Prosecution Insights
Last updated: May 29, 2026
Application No. 18/489,240

CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF

Final Rejection §102
Filed
Oct 18, 2023
Priority
Nov 08, 2016 — provisional 62/418,844 +3 more
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ramot AT Tel-Aviv University Ltd.
OA Round
4 (Final)
85%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1328 granted / 1564 resolved
+24.9% vs TC avg
Minimal -4% lift
Without
With
+-4.4%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 8m
Avg Prosecution
50 currently pending
Career history
1600
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
22.8%
-17.2% vs TC avg
§102
23.7%
-16.3% vs TC avg
§112
27.7%
-12.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1564 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 102 Rejections Withdrawn The rejection of claims 25, 28 and 29, in so far as they read on the species defined in the previous Office Action, under 35 USC 102(a)(1), outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment narrows the scope of the claimed subject matter such that it no longer reads on the cited art. Markush Search Inventor having overcome the outstanding art rejection, the search was, therefore, expanded as called for under Markush examination practice, a compound-by-compound search, to include a single additional species. That species is defined when, using Formula (II) of independent claim 25: R1=side chain of serine (HOCH2-); n=1, p=0; W=a bond; m=0; X’=O; z=2; and A= -NR2R3 where R2=R3=C12 alkyl. All claimed but as yet unexamined subject matter which does not read on the above defined species is hereby withdrawn from consideration, for purposes of this Office Action, as being drawn to non-elected subject matter. This subject matter will be rejoined as appropriate as the Markush examination progresses. Claim Rejections - 35 USC § 102, NEW In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 25, 28 and 29, in so far as they read on the species defined above, are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by FR 2687390. The reference teaches inventor’s compound (formula (II)) as a synthetic intermediate in the preparation of compounds of formula (I) (page 2, diagramed formula (II); page 4, EXAMPLE 1, -R1=R2=C12H25, n=2) The examiner notes that the reference teaches two other of inventor’s compounds as well: -R1=R2=C14H29, n=2; and -R1=R2=C16H33, n=2. Allowable Subject Matter As previously noted, the elected species being free of the prior art, claim 32, which is drawn exclusively to the elected species, is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 5/7/2026
Read full office action

Prosecution Timeline

Show 3 earlier events
Jun 18, 2025
Response Filed
Sep 03, 2025
Final Rejection mailed — §102
Oct 16, 2025
Response after Non-Final Action
Oct 31, 2025
Request for Continued Examination
Nov 05, 2025
Response after Non-Final Action
Dec 09, 2025
Non-Final Rejection mailed — §102
Mar 03, 2026
Response Filed
May 11, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637441
PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER
5y 9m to grant Granted May 26, 2026
Patent 12636334
FOAM TREATMENT METHOD FOR BACTERIA
2y 4m to grant Granted May 26, 2026
Patent 12630520
LEFT-HANDED BICYCLIC MORPHOLINE AND SALT THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE
4y 0m to grant Granted May 19, 2026
Patent 12624041
HETEROCYCLIC COMPOUND AND USE THEREOF
3y 4m to grant Granted May 12, 2026
Patent 12617014
AU, AG AND RICH PHYTOCHEMICAL PAYLOAD NANOMATERIALS, ANTIVIRAL/ANTIBACTERIAL PRODUCTS AND SYNTHESIS METHODS
2y 6m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
85%
Grant Probability
80%
With Interview (-4.4%)
1y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1564 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month